ADD ANYTHING HERE OR JUST REMOVE IT…
Wrong menu selected
Acarix Acarix
  • Product

    Background

    • What is Coronary Artery Disease (CAD)?
    • Diagnosing CAD

    About the product

    • The CADScor® System
    • How does it work
  • Resources

    Testimonials

    • HCP stories
    • Patient stories

    References

    • Clinical Studies
    • Questionnaire
    • Downloads (US)
    • Downloads (EU)
    • Education

    Support

    • Training
    • FAQ
    • Reimbursement

    Physician Locator

    • Germany
  • Investors
    • Corporate Governance
    • General Meetings
    • Financial Reports and Calendar
    • The Acarix Share
    • Rights Issue/Warrant Program
    • Previous Rights Issue
    • Investor Presentations
  • Company

    Who we are

    • About Acarix
    • leadership
    • Join the team

    Get in touch

    • Contact us
    • Investigator Initiated Study
  • News
    • Press
    • Events
    • Social Media
Account
Search
Book a Demo
Acarix Acarix
Book a demo
Menu
author-avatar acarix
Press
August 6, 2024
03 Jun 2022

Acarix signs additional commercial agreement in US and receives rapid orders in both Mississippi and Tennessee

Press release Malmö, Sweden, June 3, 2022   Acarix signs additional commercial agreement in US and receives rapid orders in both Miss...
Continue reading
author-avatar acarix
Press
August 6, 2024
11 May 2022

Kommuniké från årsstämman i Acarix

Pressmeddelande Malmö, 11 maj 2022   Kommuniké från årsstämman i Acarix Årsstämman 2022 i Acarix AB ("Acarix" eller "B...
Continue reading
author-avatar acarix
Press
August 6, 2024
11 May 2022

Announcement from Acarix’s annual general meeting

Press release Malmö, Sweden, May 11, 2022   Announcement from Acarix's annual general meeting The annual general meeting 2022 (&...
Continue reading
author-avatar acarix
Press
August 6, 2024
11 May 2022

Acarix AB (publ) publicerar delårsrapport, januari – mars 2022

Pressmeddelande Malmö, 11 maj 2022   Acarix AB (publ) publicerar delårsrapport, januari - mars 2022 Ökat momentum i verksamheten och ...
Continue reading
author-avatar acarix
Press
August 6, 2024
11 May 2022

Acarix AB (publ) publishes Interim Report, January – March 2022

Press release Malmö, Sweden, May 11, 2022   Acarix AB (publ) publishes Interim Report, January – March 2022 Increased commercial mome...
Continue reading
author-avatar acarix
Press
August 6, 2024
06 May 2022

Acarix presenterar på Naventus Health Care Summit 2022

Pressmeddelande Malmö, 6 maj 2022   Acarix presenterar på Naventus Health Care Summit 2022 Helen Ljungdahl Round, VD och koncernchef ...
Continue reading
author-avatar acarix
Press
August 6, 2024
06 May 2022

Acarix presents at Naventus Health Care Summit 2022

Press release Malmö, Sweden, May 6, 2022   Acarix presents at Naventus Health Care Summit 2022 Helen Ljungdahl Round, President and C...
Continue reading
author-avatar acarix
Press
August 6, 2024
20 Apr 2022

Acarix publishes the annual report for 2021

Press release Malmö, Sweden, April 20, 2022   Acarix publishes the annual report for 2021 Today, Wednesday April 20, Acarix is publis...
Continue reading
author-avatar acarix
Press
August 6, 2024
20 Apr 2022

Acarix publicerar årsredovisningen för 2021

Pressmeddelande Malmö, 20 april 2022   Acarix publicerar årsredovisningen för 2021 Idag, onsdagen den 20 april, publicerar Acarix sin...
Continue reading
author-avatar acarix
Press
August 6, 2024
11 Apr 2022

Kallelse till årsstämma i Acarix AB

Kallelse till årsstämma i Acarix AB Aktieägarna i Acarix AB, org.nr 559009-0667, ("Bolaget") kallas härmed till årsstämma on...
Continue reading
author-avatar acarix
Press
August 6, 2024
11 Apr 2022

Notice of Annual General Meeting in Acarix AB

Notice of Annual General Meeting in Acarix AB The shareholders of Acarix AB, reg. no. 559009-0667, (the "Company"), are here...
Continue reading
author-avatar acarix
Press
August 6, 2024
01 Apr 2022

FDA requests supplementary information for Acarix breakthrough designation request for heart failure diagnosis

Press release (MAR)Malmö, Sweden, April 1, 2022   FDA requests supplementary information for Acarix breakthrough designation request...
Continue reading
  • «
  • ‹
  • 16
  • 17
  • 18
  • 19
  • 20
  • ›
  • »
Acarix AB
Jungmansgatan 12
211 19 Malmö
SE
[email protected]

Product

Background

  • What is Coronary Artery Disease (CAD)?
  • Diagnosing CAD

About the product

  • The CADScor® System
  • How does it work

Resources

Testimonials

  • HCP stories
  • Patient stories

Support

  • Training
  • FAQ

References

  • Clinical Studies
  • Downloads (US)
  • Downloads (EU)

Investors

  • Corporate Governance
  • General Meetings
  • Financial Reports and Calendar
  • The Acarix Share
  • Rights Issue
  • Investor Presentations

Company

Who we are

  • About Acarix
  • Management
  • Join the team

Get in touch

  • Contact us
  • LinkedIn
  • Twitter

News

  • Press
  • Events
  • Cookie policy
  • Privacy Policy: Clinical Studies
  • Privacy Policy
  • Cookie policy
  • Privacy Policy: Clinical Studies
  • Privacy Policy

Acarix, 2025. All rights reserved V5

  • Products
    • Background
    • What is Coronary Artery Disease
    • Diagnosing CAD
    • About the product
    • The Cadscor System
    • How Does it Work
  • Resources
    • Testimonial
    • HCP Stories
    • Patients Stories
    • References
    • Clinical Studies
    • Downloads (US)
    • Downloads (EU)
    • Support
    • Training
    • Faq
    • Reimbursement
    • Physician Locator
    • Germany
  • Investors
    • Corporate Governance
    • General Meetings
    • Financial Reports and Calendar
    • The Acarix Share
    • Right Issue
    • Previous Rights Issue
    • Investor Presentations
  • Company
    • Who we are
    • About Acarix
    • Leadership
    • Join The Team
    • Get in touch
    • Contact Us
    • Investigator Initiated Study
  • News
    • News
    • Press
    • Events
    • Socialmedia
Start typing to see products you are looking for.